sFas levels increase in response to cisplatin-based chemotherapy in lung cancer patients

• Published in: Cell biochemistry and function 2010-10, Vol.28 (7), p.565-570
• Main Authors: Ulukaya, Engin, Acilan, Ceyda, Yilmaz, Meryem, Yilmaztepe-Oral, Arzu, Ari, Ferda, Zik, Berrin, Ursavas, Ahmet, Tokullugil, Asuman H.
• Format: Article
• Language: English
• Subjects: Aged; Antineoplastic Agents - pharmacology; Antineoplastic Agents - therapeutic use; apoptosis; Biomarkers, Tumor - blood; chemotherapy; Cisplatin - pharmacology; Cisplatin - therapeutic use; Fas; Fas Ligand Protein - metabolism; fas Receptor - blood; fas Receptor - metabolism; Female; Humans; Immunohistochemistry; Inhibitor of Apoptosis Proteins; lung cancer; Lung Neoplasms - diagnosis; Lung Neoplasms - drug therapy; Lung Neoplasms - metabolism; Lung Neoplasms - pathology; Male; Microtubule-Associated Proteins - blood; Microtubule-Associated Proteins - metabolism; Middle Aged; Prognosis; sFas; Survival Analysis; survivin
• ISSN: 0263-6484; 1099-0844
• DOI: 10.1002/cbf.1689

The Fas/Fas Ligand (FasL) system and survivin have counteracting roles in cell survival. Therefore, we explored the role of circulating soluble Fas (sFas) and the tissue levels of Fas and survivin with regard to response to chemotherapy in lung cancer patients. Serum samples from 52 lung cancer patients and 54 control subjects (19 benign lung disease and 35 healthy control subjects) were collected prior to and 24 and 48 h after chemotherapy. sFas was statistically significantly higher in the cancer group than that in the control groups (p